Objective:
To evaluate the real-world outcomes of combining trabecular microbypass stents and cataract surgery with or without an intracameral travoprost implant in lowering intraocular pressure (IOP) and reducing the need for topical medications in glaucoma patients.
Key Findings:
- Statistically significant reduction in IOP of 1.9 mmHg in the iStent Infinite group and 2.6 mmHg in the iStent Infinite with iDose TR group.
- 29% of patients in the iStent Infinite group had IOP <10 mmHg post-surgery vs 8% pre-surgery; 54% were medication-free vs 8% pre-surgery.
- 44% of patients in the iStent Infinite with iDose TR group had IOP <10 mmHg post-surgery vs 12% pre-surgery; 88% were medication-free vs 26% pre-surgery.
- No treatment-related adverse events reported.
Interpretation:
Combining trabecular microbypass stents with cataract surgery, especially with the addition of iDose TR, significantly lowers IOP and reduces the need for topical medications, improving patient quality of life.
Limitations:
- Small sample size of 49 patients.
- Retrospective design may limit generalizability.
Conclusion:
The study supports the effectiveness of combining MIGS with cataract surgery in managing glaucoma, highlighting the benefits of reduced IOP and medication burden.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.